The clinical evidence for postbiotics as microbial therapeutics

Thumbnail Image
Mosca, Alexis
Abreu Y Abreu, Ana Teresa
Gwee, Kok Ann
Ianiro, Gianluca
Tack, Jan
Nguyen, Thi Viet Ha
Hill, Colin
Journal Title
Journal ISSN
Volume Title
Taylor & Francis
Research Projects
Organizational Units
Journal Issue
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy.
Microbiota , Postbiotics , Microbial therapeutics , Clinical benefits , Gastrointestinal disorders , Allergy , Upper respiratory tract infection , Stress , Metabolic syndrome
Mosca, A., Abreu Y Abreu, A.T., Gwee, K.A., Ianiro, G., Tack, J., Nguyen, T.V.H. and Hill, C. (2022) ‘The clinical evidence for postbiotics as microbial therapeutics’, Gut Microbes, 14(1), 2117508 (14pp). doi: 10.1080/19490976.2022.2117508
Link to publisher’s version